Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - Armata Pharmaceuticals reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of 47.37% [1] - The company posted revenues of $0.49 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 64.42%, and down from $0.97 million in the same quarter last year [2] - Over the last four quarters, Armata Pharmaceuticals has surpassed consensus EPS estimates three times but has only topped consensus revenue estimates once [2] Stock Outlook - Armata Pharmaceuticals shares have declined approximately 23.2% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $1.38 million, and for the current fiscal year, it is -$1.94 on revenues of $5.5 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Armata Pharmaceuticals belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]